New FDA guidelines shift alcohol approvals toward the harm-reduction model
STUDY: Bramness JG et al, Eur Addict Res 2026
STUDY TYPE: Editorial
FUNDING: Independent
Background
For decades, the FDA required total abstinence as the only valid success measure in pharmacological trials for alcohol use disorder. That standard excluded many patients who couldn’t or wouldn’t pursue abstinence and made it hard to appreciate medications like naltrexone and nalmefene that reduce drinking without eliminating it.
This editorial reviews the decision, drawing on 27 observational studies and 7 pharmacotherapy trials showing that drinking reductions produce meaningful health benefits.
A major review found that moving down at least two WHO risk levels correlates with lower rates of alcohol dependence, improved liver function, fewer psychiatric symptoms, better quality of life, and less healthcare use.
In three phase III trials, the reduced-drinking endpoint produced comparable or larger effect sizes than abstinence-based outcomes, with higher overall response rates. Only one in six patients with alcohol use disorder currently receives adequate treatment, and abstinence-only goals likely contribute to that gap.
Practice Implications
- This change brings approvals more in line with the realities of practice.
- Reducing drinking is a legitimate goal, and more achievable for some patients.
— Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
